Which module was it made on, and who published it

An index of radiotracers and the automated syntheses reported for them: module, cassette, purification, yield, precursor and its supplier — each value traceable to the paper it came from. Diagnostic agents and their therapeutic counterparts sit side by side.

Find a tracer

Every agent with the syntheses published for it, the modules used and the precursors behind them.

Browse 647 agents
For radiochemists and production teams

Start from the disease

Pick an indication and see what exists for it — imaging agents and the therapies paired with them, with how far each has got.

Browse indications
For nuclear medicine physicians

Compare modules

What has actually been produced on each platform, by whom, and with what purification.

Browse 66 platforms
For anyone specifying equipment

Theranostic pairs

Where an imaging agent and a therapy share the same targeting ligand
Prostate-specific membrane antigen (PSMA / glutamate carboxypeptidase II)
Imaging[68Ga]Ga-PSMA-11→Therapy[177Lu]Lu-PSMA-617
Prostate-specific membrane antigen (PSMA)
Imaging[18F]PSMA-1007→Therapy[177Lu]Lu-PSMA-617
Prostate-specific membrane antigen (PSMA)
Imaging[18F]DCFPyL→Therapy[177Lu]Lu-PSMA-617
Somatostatin receptor subtype 2 (SSTR2)
Imaging[68Ga]Ga-DOTATATE→Therapy[177Lu]Lu-DOTATATE
Somatostatin receptor subtype 2 (SSTR2)
Imaging[64Cu]Cu-DOTATATE→Therapy[177Lu]Lu-DOTATATE
Fibroblast activation protein (FAP)
Imaging[68Ga]Ga-FAPI-46→Therapy[177Lu]Lu-FAPI-46
SSTR2
Imaging[18F]FET-bAG-TOCA→Therapy[177Lu]Lu-DOTATATE
FAP
Imaging[18F]AlF-OncoFAP-NODAGA→Therapy[177Lu]Lu-OncoFAP-DOTAGA

Why we built this

tracer.nuclear brings together everything behind a radiopharmaceutical: cyclotrons, synthesis modules, precursors and consumables, and the quality control equipment that lets you release the product.

We believe the end product is not a module or a precursor. It is a finished tracer that leads to the right diagnosis or the right therapy.

The same holds for theranostics. Imaging with the gallium form of a ligand and treating with the lutetium form is one programme, not two. Where a pair exists, this index links both sides.

And we want radiochemists and physicians to understand each other. One side solves for yield, purity and release; the other for image quality, timing and what the scan answers. Both sets of facts belong in one place.

What is in here

Every radiopharmaceutical we could find a published synthesis for, with the module, cassette, purification, yield, precursor and supplier behind it. Each value traceable to the sentence it came from. Alongside it: quality control requirements, regulatory status checked against the registers, theranostic pairs linked to each other, and platforms ranked by what has actually been published on them.

Coverage is uneven and we say so. A well-studied tracer has dozens of reports, a research compound often one, and an empty field means the literature did not say.

Read how this index is built.

Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region — tell us what you need.

Get in touch

Spotted something wrong, or want to contribute?Corrections to any entry are welcome, and so is joining as a contributing expert — reviewing a tracer class, a module, or the quality control requirements in your field.

Write to us